Security Snapshot

VANECK ETF TRUST - PHARMACEUTCL ETF (PPH) Institutional Ownership

CUSIP: 92189F692

13F Institutional Holders and Ownership History from Q1 2016 to Q1 2026

Latest Period

Q1 2026

Institutions Reporting

149

Shares (Excl. Options)

7,596,458

Price

$103.88

Save this security page for your next review

Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.

Latest holder snapshot 5 signals
Portfolio coverage rank
0%
Share change
-468,193
Value change
-$48,054,665
Number of holders
149
Issuer context Names, identifiers, and filing context for this profile. 1 identity field
SEC-reported price per share
$101.17
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors

Key facts

  • PPH - VANECK ETF TRUST - PHARMACEUTCL ETF is tracked under CUSIP 92189F692.
  • 149 institutions reported positions in Q1 2026.
  • Schedule 13D/13G significant owner rows are not currently available.

Change

  • Holder count moved from 146 to 149 between Q4 2025 and Q1 2026.
  • SEC-reported value moved from $806,342,257 to $789,032,446.

Research use

  • You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
  • 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.

Evidence

Source: SEC Form 13F

Latest holder context comes from 149 institutions filings for Q1 2026.

Open SEC evidence

Security key

92189F692

Latest holder period

Q1 2026

13F holders

149

13D/G owners

0

CIK / CUSIP context first

As of 31 Mar 2026, 149 institutional investors reported holding 7,596,458 shares of VANECK ETF TRUST - PHARMACEUTCL ETF (PPH).

Quarter history

Institutional holders across reporting periods

Holder count, reported shares/value, and median price by quarter.

Periods
41
Latest
Q1 2026
Rows shown
1-25 of 41
Period 13F Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2026 Q1 7,596,458 $789,032,446 -$48,054,665 $103.88 149
2025 Q4 7,815,514 $806,342,257 -$22,533,973 $103.17 146
2025 Q3 7,887,542 $712,684,813 +$11,919,837 $90.36 124
2025 Q2 7,771,917 $683,617,119 +$174,839,485 $87.96 126
2025 Q1 5,812,878 $529,776,765 -$16,593,374 $91.13 133
2024 Q4 5,968,612 $514,991,591 +$11,463,960 $86.28 140
2024 Q3 5,722,368 $543,596,181 +$86,910,938 $95.03 140
2024 Q2 4,815,475 $440,503,835 +$20,148,731 $91.48 139
2024 Q1 4,560,967 $413,738,555 -$6,570,269 $90.70 135
2023 Q4 4,735,950 $385,640,268 -$16,334,775 $81.37 108
2023 Q3 5,055,242 $403,877,688 +$20,782,635 $79.86 101
2023 Q2 4,968,295 $391,351,030 +$6,082,356 $78.77 101
2023 Q1 4,592,895 $356,545,144 -$174,679,110 $77.63 104
2022 Q4 6,556,396 $509,704,617 +$29,919,137 $77.74 111
2022 Q3 6,321,313 $426,561,742 +$118,107,484 $67.24 85
2022 Q2 4,502,840 $345,999,696 +$274,153,350 $76.84 90
2022 Q1 882,288 $70,469,084 +$7,531,365 $79.76 74
2021 Q4 769,399 $59,210,150 -$6,214,856 $76.95 61
2021 Q3 775,415 $56,458,804 +$3,053,753 $72.81 49
2021 Q2 861,370 $62,932,502 -$121,700,494 $73.07 52
2021 Q1 2,722,467 $187,899,411 +$79,801,407 $69.02 51
2020 Q4 1,391,267 $92,698,931 -$36,792,997 $66.48 48
2020 Q3 1,950,775 $121,269,474 +$26,966,047 $62.17 46
2020 Q2 1,517,324 $94,463,969 +$34,775,889 $62.25 47
2020 Q1 1,060,989 $57,742,871 -$79,299,356 $54.39 44
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .